Space Solar Cell Production Faces Capacity Constraints on IRIS2 Buildout

Summary
Eutelsat booked EUR 8.9 billion of IRIS2 backlog as construction began; 5N Plus, sold out through 2027, is weighing a far larger space solar cell expansion.
Europe's IRIS2 satellite constellation has entered construction, and the order flow is now reaching the component supply chain. Between October 29 and November 3, 2026, satellite operator Eutelsat (EUTLF) and space solar-cell maker 5N Plus (FPLSF) both said on their earnings calls that the EU-backed network has moved from planning to building: Eutelsat booked EUR 8.9 billion of backlog, and 5N Plus began evaluating a much larger capacity expansion for European demand in 2029-2031 [1][2].
How an IRIS2 construction contract flows down the supply chain
IRIS2 is Europe's largest public-private partnership in space, a multi-orbit communications constellation meant to be under European control [3]. It is built and run by the SpaceRISE consortium of Eutelsat, SES and Hispasat. Eutelsat leads the low-Earth-orbit (LEO) layer, the one closest to the ground, and treats it as the second generation of its own LEO network [3]. In August 2026, Eutelsat said the programme had passed its first milestone and moved into construction [3].
Construction work moves down in layers. The operator signs the build contract and books it as backlog, then subcontracts most satellite manufacturing to primes such as Airbus and Thales, which in turn buy key components from suppliers. 5N Plus management expects the primes that won constellation work to finalize supply arrangements with all their key component suppliers during 2027, in time for 2029-2031 launches [2]. Satellites run on solar cells, and few Western companies make space-grade cells. 5N Plus's German subsidiary AZUR SPACE is one of them; in May 2026 the company said the market had only two other competitors and capacity was maxed out [4]. IRIS2 demand lands on top of continued growth in North American constellations, so component capacity is the first thing being tested [2].
The backlog sits with the operator; the capacity squeeze sits with the cell maker
Eutelsat's EUR 8.9 billion backlog has barely reached its profit and loss yet. On its October 29 call, the company said IRIS2 had formally entered construction, that the revenue will be recognized mostly in fiscal years 2027-2031, and that only about EUR 5 million was recognized in the first quarter [1]. The CFO added that most of this construction revenue is subcontracted and will carry a margin well below the group's [1].
5N Plus's disclosures show demand already exceeding current capacity. In August, the company said its space solar capacity for 2026 and 2027 was sold out and that the dollar value of bids placed in the first half was at least twice the prior-year period [5]. On November 3, the CEO said European opportunities plus North American growth mean the company needs to "think much bigger." Its past pace of adding 25%-35% capacity a year may not be enough, and it is evaluating more drastic options to capture European orders for 2029-2031, funded by debt plus customer contributions and partnerships [2].
Taken together, the two disclosures show IRIS2 has turned from a policy document into a procurement plan with amounts and timelines. So far, though, only a small part has reached the income statement, and 5N Plus has not announced the size of its expansion.
Early gains concentrate in scarce components; operator returns come later
Along this chain, pricing power is more likely to sit with capacity-constrained components. Eutelsat's construction revenue is largely low-margin pass-through [1], and its larger return may only show once the second-generation LEO network enters service [3]. Components such as solar cells, with few qualified suppliers and capacity already booked, may instead secure multi-year orders during the 2027 procurement window, with customers willing to help fund expansion [2].
This view has limits. The 5N Plus CEO said upstream germanium supply is ample, so the constraint is cell manufacturing capacity, not raw material [2]. Three things are worth tracking: whether 5N Plus announces a concrete expansion plan and customer funding arrangements in 2027, when Eutelsat's IRIS2 backlog starts converting into revenue at scale, and whether SES discloses a similar construction contract.
Companies exposed to this change
- SES (SGBAF): The other operator in the IRIS2 consortium, responsible for the 18-satellite medium-Earth-orbit layer. In July it said IRIS2 negotiations were in their final stages and that its roughly $700 million of 2026 capex already includes the programme. It may face the same construction-phase backlog and low-margin subcontracting structure as Eutelsat, but it has not disclosed a corresponding backlog figure [6].
- Rocket Lab (RKLB): Describes itself as the world's largest space-grade solar manufacturer and positions its German subsidiary as a domestic European constellation supplier. If AZUR SPACE capacity falls short during the 2027 procurement window, some cell orders could go to Rocket Lab, but the company has not mentioned IRIS2 [7].
- Airbus (AIR.PA): European aerospace group and one of the main primes taking Eutelsat's subcontracted satellite manufacturing. Its manufacturing revenue could grow as IRIS2 advances, but the research contains no direct disclosure from Airbus on the programme.
Sources
[1] Drillr · Eutelsat (EUTLF) · 2026-10-29 · Q1 FY2026-27 earnings call
[2] Drillr · 5N Plus (FPLSF) · 2026-11-03 · Q3 2026 earnings call
We're looking at different options to do something much more drastic in order to capture The opportunities arising in Europe for those years 29, 30, and 31.
[3] Drillr · Eutelsat (EUTLF) · 2026-08-07 · FY2026 earnings call
[4] Drillr · 5N Plus (FPLSF) · 2026-05-07 · Q1 2026 earnings call
[5] Drillr · 5N Plus (FPLSF) · 2026-08-04 · Q2 2026 earnings call
[6] Drillr · SES (SGBAF) · 2026-07-31 · Q2 and H1 2026 earnings call
[7] Drillr · Rocket Lab (RKLB) · 2026-08-10 · Q2 2026 earnings call
This is meant to help you spot industry changes and companies that may be overlooked. It is not a stock recommendation.